Latest News and Press Releases

CHESTERBROOK, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced the appointment of Mark Demitrack, M.D., as Senior Vice President and Chief Medical Officer.  Dr....

CHESTERBROOK, Pa., May 08, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved,...

– First license agreements for ex-US development and commercialization of oliceridine add potential revenue streams –             – Oliceridine NDA on track for potential approval in November – ...

CHESTERBROOK, Pa., May 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Deutsche Bank 43rd Annual Healthcare Conference on Tuesday, May 8th,...

– Nhwa granted a license to develop, manufacture, and commercialize oliceridine in China – – Trevena to receive upfront and milestone payments and royalties – CHESTERBROOK, Pa. and XUZHOU,...

– Pharmbio Korea granted a license to develop, manufacture, and commercialize oliceridine in South Korea – – Trevena to receive upfront and milestone payments and royalties – CHESTERBROOK, Pa. and...

CHESTERBROOK, Pa., April 26, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call and webcast on Thursday, May 3, 2018 at 8:00 am EDT to review...

CHESTERBROOK, Pa., April 05, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that President and Chief Executive Officer Maxine Gowen, Ph.D., will retire on October 1, 2018.  The...

CHESTERBROOK, Pa., March 20, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Needham & Company 17th Annual Healthcare Conference on...

CHESTERBROOK, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Oppenheimer & Company 28th Annual Healthcare Conference on...